12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

E2609: Preliminary Phase I data

Preliminary data from the double-blind, U.S. Phase I A001-002 trial in 50 healthy volunteers showed that multiple ascending-doses of E2609 significantly reduced the concentration of amyloid beta in cerebrospinal fluid (CSF) from...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >